Premenopausal ER+ breast cancer recurrence reduced significantly with aromatase inhibitors
December 22nd 2021Compared with tamoxifen, aromatase inhibitors were revealed to be more effective in reducing the rate of recurrence in ER+ breast cancer among premenopausal women receiving ovarian suppression.
Read More